INSR and metastatic colorectal cancer: Clinical trials on colorectal cancer patients largely failed when EVE was used as a single agent [24, 25] or combined with the anti-VEGF-A antibody bevacizumab [26] or the insulin receptor/insulin-like growth factor R receptor inhibitor linsitinib [27] for the treatment of refractory metastatic colorectal cancer.